Press Release

Analysis of Europe Human Insulin Market 2019-2024: Industry Trends, Share, Size, Price, Revenue, Business Strategy, Production Technology Forecast to 2024

Europe

The “Europe Human Insulin Market” research report 2019-2024 delivers comprehensive information and valuable insights about the Europe Human Insulin industry. The information available in the Europe Human Insulin market report is not only based on the facts but also on the case studies, which analysts have included to convey appropriate information to the clients in a well-versed manner. Europe Human Insulin market report includes valuable information to assist new entrants, as well as established players, to understand the prevailing trends in the market.

Some Companies Are Covered in the Europe Human Insulin Market:

  • Novo Nordisk
  • Eli Lilly
  • Sanofi
  • Biocon

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/14245107

    Market Overview:

  • The European human insulin market is expected to register a CAGR of 4.3% during the forecast period (2019-2024), and it is estimated to reach USD 4.5 billion by 2019.
  • – Diabetes is generally considered as a lifestyle-related disease. Over time, incidences of the disease have increased outrageously, with the increase in population levels.
  • – Prevalence of diabetes among all age groups in the European region is increasing mainly due to obesity, unhealthy diet and physical inactivity.
  • – The prevalence of autoimmune Type 1 Diabetes is also rising in Europe, and as per sources, Europe has the highest number of children with Type 1 Diabetes. The European countries that are making the most significant contribution to the overall numbers of Type 1 Diabetes in children are the United Kingdom, the Russian Federation, and Germany.
  • – This has resulted in a massive demand for insulin. Though Type 2 Diabetic patient’s treatment is initiated with oral drugs, insulin may also be required when glucose levels are not effectively controlled, due to the unhealthy lifestyle. Thus, a demand for insulin even exists among Type 2 Diabetic patients.

    Scope of the Report:

  • The market is segmented by Product Type (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), and Geography.

    Reasons for Buying Europe Human Insulin Market Report:

    • This report provides pin-point analysis for changing competitive dynamics
    • It provides a forward looking perspective on different factors driving or restraining market growth
    • It provides a five-year forecast assessed on the basis of how the market is predicted to grow
    • It helps in understanding the key product segments and their future
    • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
    • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/14245107

    Key Market Trends:

    The rise in Insulin Drug Pricing

    – Insulins have been in the market for decades. However, the cost of insulin has always been a primary concern.
    – A recent example is the pull-out of Tresiba from Germany due to the pricing pressure after the authorities said they would price the long-acting basal insulin on par with old human insulin injections.
    – Though biosimilar competition in Europe increased, allowing for insulin prices to be low, branded drugs have always been the order of the day.
    – Moreover, leading players have been able to get multiple extensions by making incremental improvements to their branded drugs.

    Germany Dominates the Market

    – As of 2018, Germany dominated the insulin market, and it is expected to continue its dominance during the forecast period. The rise is due to the high prevalence of diabetes among the country’s population.
    – In Germany, according to an estimate, the number of patients with Type 1 and Type 2 diabetes is gradually increasing.
    – The diabetic population in Germany, as of 2018, was reported to be 7.9 million.
    – The number is expected to increase many-fold in the coming years due to the increasing prevalence of sedentary lifestyles, changing food habits, and other lifestyle changes.

    Europe Human Insulin Market Report Provides Comprehensive Analysis of:

    • Functional market industry outline
    • Up and downstream industry examination
    • Channels and propositions believability
    • Market challenge by key players
    • Enhancement suggestions examination

    Purchase this Report (Price 4000 USD for single user license) – https://www.industryresearch.co/purchase/14245107

    Report Highlights:

    • Market Dynamics – Drivers, Restraints, and Opportunities
    • Market Segmentation – Types, Applications, Regions, and Technology
    • Market Trends
    • Competitive Landscape
    • SWOT Analysis and Porter’s Five Forces Analysis

    Detailed TOC of Europe Human Insulin Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug
    5.1.1 Insulin (Value and Volume, 2012-2024)
    5.1.1.1 Basal or Long-acting Insulins
    5.1.1.1.1 Lantus (Insulin Glargine)
    5.1.1.1.2 Levemir (Insulin Detemir)
    5.1.1.1.3 Toujeo (Insulin Glargine)
    5.1.1.1.4 Tresiba (Insulin Degludec)
    5.1.1.1.5 Basaglar (Insulin Glargine)
    5.1.1.2 Bolus or Fast-acting Insulins
    5.1.1.2.1 NovoRapid\Novolog (Insulin Aspart)
    5.1.1.2.2 Humalog (Insulin Lispro)
    5.1.1.2.3 Apidra (Insulin Glulisine)
    5.1.1.3 Traditional Human Insulins
    5.1.1.3.1 Novolin\Actrapid\Insulatard
    5.1.1.3.2 Humilin
    5.1.1.3.3 Insuman
    5.1.1.4 Biosimilar Insulins
    5.1.1.4.1 Insulin Glargine Biosimilars
    5.1.1.4.2 Human Insulin Biosimilars
    5.1.1.5 Insulin Combinations
    5.1.1.5.1 NovoMix (Biphasic Insulin Aspart)
    5.1.1.5.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
    5.1.1.5.3 Xultophy (Insulin Degludec and Liraglutide)
    5.2 Geography
    5.2.1 Europe (Value and Volume, 2012-2024)
    5.2.1.1 United Kingdom
    5.2.1.1.1 Basal or Long-acting Insulins
    5.2.1.1.2 Bolus or Fast-acting Insulins
    5.2.1.1.3 Traditional Human Insulins
    5.2.1.1.4 Biosimilar Insulins
    5.2.1.1.5 Insulin Combinations
    5.2.1.2 Germany
    5.2.1.2.1 Basal or Long-acting Insulins
    5.2.1.2.2 Bolus or Fast-acting Insulins
    5.2.1.2.3 Traditional Human Insulins
    5.2.1.2.4 Biosimilar Insulins
    5.2.1.2.5 Insulin Combinations
    5.2.1.3 France
    5.2.1.3.1 Basal or Long-acting Insulins
    5.2.1.3.2 Bolus or Fast-acting Insulins
    5.2.1.3.3 Traditional Human Insulins
    5.2.1.3.4 Biosimilar Insulins
    5.2.1.3.5 Insulin Combinations
    5.2.1.4 Russia
    5.2.1.4.1 Basal or Long-acting Insulins
    5.2.1.4.2 Bolus or Fast-acting Insulins
    5.2.1.4.3 Traditional Human Insulins
    5.2.1.4.4 Biosimilar Insulins
    5.2.1.4.5 Insulin Combinations
    5.2.1.5 Spain
    5.2.1.5.1 Basal or Long-acting Insulins
    5.2.1.5.2 Bolus or Fast-acting Insulins
    5.2.1.5.3 Traditional Human Insulins
    5.2.1.5.4 Biosimilar Insulins
    5.2.1.5.5 Insulin Combinations
    5.2.1.6 Italy
    5.2.1.6.1 Basal or Long-acting Insulins
    5.2.1.6.2 Bolus or Fast-acting Insulins
    5.2.1.6.3 Traditional Human Insulins
    5.2.1.6.4 Biosimilar Insulins
    5.2.1.6.5 Insulin Combinations
    5.2.1.7 Rest of Europe
    5.2.1.7.1 Basal or Long-acting Insulins
    5.2.1.7.2 Bolus or Fast-acting Insulins
    5.2.1.7.3 Traditional Human Insulins
    5.2.1.7.4 Biosimilar Insulins
    5.2.1.7.5 Insulin Combinations

    6 MARKET INDICATORS
    6.1 Type-1 Diabetes Population (2012-2024)
    6.2 Type-2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 Company Profiles
    7.1.1 Novo Nordisk
    7.1.2 Eli Lilly
    7.1.3 Sanofi
    7.1.4 Biocon
    7.2 Company Share Analysis
    7.2.1 Novo Nordisk
    7.2.2 Eli Lilly
    7.2.3 Sanofi

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Milk Tank Market 2019: Global Size, Industry Share, Outlook, Trends Evaluation, Geographical Segmentation, Business Challenges and Opportunity Analysis till 2024

    Attapulgite Market 2019 | Shares & Revenue, Deployment Mode, Emerging Technology, Industry Vertical, and Competitive Vendors in Top Regions- Global Forecast to 2026

    Lab Scales Market 2019 Industry Share, Size, Segmentation, Application, Technology, Trends and Opportunities Forecasts to 2025

    Global Tungsten Welding Electrodes Market Share, Growth, Trend Analysis and Forecast from 2019-2025; Consumption Capacity by Volume and Production Value

    Tags
  • Alfredoo Epps

    Alfredo Epps is a finance expert heading the petroleum column. He joined the group last year as an associate writer. But his thorough research skills and ability to seamlessly putting numerical data into words helped him get a senior position. Apart from a column head, Alfredo is a dancer and a violinist.

    Related Articles

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    Close